Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 44D0677386	(X3) Date Survey Completed 08/23/2022
Name of Provider or Supplier Memphis Childrens Clinic	**Street Address, City, State** 7705 Poplar Ave Suite 230 Bldg B, Germantown, TN	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D6004	LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(a)(b) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (a) The laboratory director, if qualified, may perform the duties of the technical consultant, clinical consultant, and testing personnel, or delegate these responsibilities to personnel meeting the qualifications of 493.1409, 493.1415, and 493.1421, respectively. (b) If the laboratory director reapportions performance of his or her responsibilities, he or she remains responsible for ensuring that all duties are properly performed. This STANDARD is not met as evidenced by: Based on review of the Centers for Medicare and Medicaid Services (CMS) Laboratory Personnel Report (Form CMS-209) and the CMS ASPEN database, lack of documentation, interview with the lead testing person, search of CMS ASPEN database and review of a letter from technical consultant number two, the laboratory director (LD) failed to notify CLIA of change in LD within 30 days of the change. The findings include: 1. Review of the Form CMS-209 and the CMS ASPEN database revealed the LD on the Form-CMS 209 did not match the LD of record in the CMS ASPEN database. 2. Request for documentation of notification to the state agency of change in LD to the lead testing person on August 23, 2022 at approximately 11:00 am revealed no documents were available. 3. During an interview on August 23, 2022 at 1:00 pm, the lead testing person stated the current LD took over shortly after the 2019 survey. 4. Search of the CMS ASPEN database revealed no evidence that the state agency had been notified of the LD change. 5. Review of a letter received on August 24, 2022 from technical consultant number two dated August 22, 2022, revealed the current LD took over responsibilities on October 7, 2020. The LD failed

	to notify CLIA of change in laboratory director within 30 days of the change as required at 493.51.